Devi SenGupta

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Jason D. Goldman, David Chien Lye, David S.C. Hui et al. · New England Journal of Medicine · 2020 · 1.4K citations · Full text

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19

Christoph D. Spinner, Robert Gottlieb, Gerard J. Criner et al. · JAMA · 2020 · 1.3K citations · Full text

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

Paul E. Sax, Anton Pozniak, Marisa Montes et al. · The Lancet · 2017 · 385 citations

Hiv/aids Counselling, Antiviral Drug Development, Antiviral Therapy +11

Consistent Cytotoxic-T-Lymphocyte Targeting of Immunodominant Regions in Human Immunodeficiency Virus across Multiple Ethnicities

Nicole Frahm, Bette Korber, Craig Adams et al. · Journal of Virology · 2004 · 274 citations · Full text

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment

Anton Pozniak, José Ramón Arribas, Joseph Gathe et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2015 · 184 citations · Full text